Abstract
Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Current Drug Safety
Title: Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment
Volume: 2 Issue: 1
Author(s): Bensu Karahalil, Seyhan Yagar and Yasemin Ozin
Affiliation:
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Abstract: Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Export Options
About this article
Cite this article as:
Karahalil Bensu, Yagar Seyhan and Ozin Yasemin, Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315426
DOI https://dx.doi.org/10.2174/157488607779315426 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell Adhesion Molecules and Cadmium
Current Chemical Biology Impact of Human Immune Deficiency Virus Infection on Hepatitis C Virus Infection and Replication
Current HIV Research Phosphorylation-Specific Prolyl Isomerase Pin1 as a new Diagnostic and Therapeutic Target for Cancer
Current Cancer Drug Targets New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry The New Challenges of Brain PET Imaging Technology
Current Medical Imaging Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly
Current Molecular Medicine Kinase Inhibitors in Multitargeted Cancer Therapy
Current Medicinal Chemistry Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation
Current Pharmacogenomics and Personalized Medicine Methodological Issues of Clinical Research with EGFR Inhibitors
Current Cancer Therapy Reviews Nanotherapeutics in Tumour Microenvironment for Cancer Therapy
Nanoscience & Nanotechnology-Asia Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets